» Articles » PMID: 31712839

Development of a Neural Rosette Formation Assay (RoFA) to Identify Neurodevelopmental Toxicants and to Characterize Their Transcriptome Disturbances

Abstract

The first in vitro tests for developmental toxicity made use of rodent cells. Newer teratology tests, e.g. developed during the ESNATS project, use human cells and measure mechanistic endpoints (such as transcriptome changes). However, the toxicological implications of mechanistic parameters are hard to judge, without functional/morphological endpoints. To address this issue, we developed a new version of the human stem cell-based test STOP-tox. For this purpose, the capacity of the cells to self-organize to neural rosettes was assessed as functional endpoint: pluripotent stem cells were allowed to differentiate into neuroepithelial cells for 6 days in the presence or absence of toxicants. Then, both transcriptome changes were measured (standard STOP-tox) and cells were allowed to form rosettes. After optimization of staining methods, an imaging algorithm for rosette quantification was implemented and used for an automated rosette formation assay (RoFA). Neural tube toxicants (like valproic acid), which are known to disturb human development at stages when rosette-forming cells are present, were used as positive controls. Established toxicants led to distinctly different tissue organization and differentiation stages. RoFA outcome and transcript changes largely correlated concerning (1) the concentration-dependence, (2) the time dependence, and (3) the set of positive hits identified amongst 24 potential toxicants. Using such comparative data, a prediction model for the RoFA was developed. The comparative analysis was also used to identify gene dysregulations that are particularly predictive for disturbed rosette formation. This 'RoFA predictor gene set' may be used for a simplified and less costly setup of the STOP-tox assay.

Citing Articles

A computational dynamic systems model for prediction of neural tube closure defects.

Berkhout J, Glazier J, Piersma A, Belmonte J, Legler J, Spencer R Curr Res Toxicol. 2025; 8:100210.

PMID: 40034255 PMC: 11875186. DOI: 10.1016/j.crtox.2024.100210.


RosetteArray Platform for Quantitative High-Throughput Screening of Human Neurodevelopmental Risk.

Lundin B, Knight G, Fedorchak N, Krucki K, Iyer N, Maher J bioRxiv. 2024; .

PMID: 38798648 PMC: 11118315. DOI: 10.1101/2024.04.01.587605.


Transcriptome-based prediction of drugs, inhibiting cardiomyogenesis in human induced pluripotent stem cells.

Cherianidou A, Kappenberg F, Seidel F, Acharya A, Papazoglou P, Srinivasan S Cell Death Discov. 2023; 9(1):321.

PMID: 37644023 PMC: 10465524. DOI: 10.1038/s41420-023-01616-6.


A Shared Pathogenic Mechanism for Valproic Acid and Knockout in a Brain Organoid Model of Neural Tube Defects.

Takla T, Luo J, Sudyk R, Huang J, Walker J, Vora N Cells. 2023; 12(13).

PMID: 37443734 PMC: 10340169. DOI: 10.3390/cells12131697.


G × E interactions as a basis for toxicological uncertainty.

Suciu I, Pamies D, Peruzzo R, Wirtz P, Smirnova L, Pallocca G Arch Toxicol. 2023; 97(7):2035-2049.

PMID: 37258688 PMC: 10256652. DOI: 10.1007/s00204-023-03500-9.